Fig. 5 |. MYH11⁺αSMA⁺ CAF are correlated with decreased T cell infiltration in tumor nests.

A, Representative examples of IHC stains from NSCLC tumors with and without MYH11⁺αSMA⁺ CAF present, showing CD3⁺ cell exclusion from tumor nests when MYH11⁺αSMA⁺ CAF are present. B, The presence or absence of MYH11⁺αSMA⁺ CAF demonstrates significant differences in tumor infiltrating CD3⁺ or CD8⁺ cells per mm² (left) and the ratio of CD3⁺ or CD8⁺ cells per mm² in the tumor versus stroma (right). Only early stage (tumor stage 1) patients were included to eliminate bias due to MYH11⁺αSMA⁺ CAF rarely being found at later stage. C, Representative images of MYH11 staining in multiple pathologies and histological subtypes. All scale bars are 250μm. (Barplot) MYH11⁺αSMA⁺ CAF distribution in different pathologies and histological subtypes in NSCLC. Significance determined by t test. D, MYH11 staining from The Human Protein Atlas. E, Quantification of 500×500μm tiles of both MYH11⁺αSMA⁺ CAF score, estimating tumor proximity of MYH11⁺αSMA⁺ cells by quantifying their enrichment within 10μm from tumor cells versus regions 20μm-30μm from tumor cells, and tumor infiltrating CD3⁺ cells per mm². A high MYH11⁺αSMA⁺ CAF score is significantly anti-correlated (Pearson) with the number of tumor infiltrating CD3⁺ cells relative to the stroma. F, Visualization of the tiling described in E. (Bottom panel) Histological scoring of a tumor lesion highlighting that a high MYH11⁺αSMA⁺ CAF score is associated more with acinar/papillary phenotype, rather than lepidic.